DE BELLIS, MICHELA
 Distribuzione geografica
Continente #
NA - Nord America 3.648
EU - Europa 719
AS - Asia 329
OC - Oceania 5
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.704
Nazione #
US - Stati Uniti d'America 3.644
CN - Cina 281
SE - Svezia 212
IT - Italia 129
UA - Ucraina 91
FI - Finlandia 66
DE - Germania 59
BE - Belgio 57
GB - Regno Unito 55
FR - Francia 24
VN - Vietnam 20
IE - Irlanda 12
IN - India 9
JP - Giappone 8
NL - Olanda 5
CA - Canada 4
CZ - Repubblica Ceca 4
AU - Australia 3
ID - Indonesia 3
IR - Iran 3
RU - Federazione Russa 3
CL - Cile 2
NZ - Nuova Zelanda 2
EE - Estonia 1
ES - Italia 1
EU - Europa 1
HK - Hong Kong 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
TR - Turchia 1
Totale 4.704
Città #
Fairfield 499
Woodbridge 385
Chandler 353
Ashburn 276
Houston 269
Cambridge 227
Jacksonville 216
Wilmington 197
Seattle 192
Nyköping 188
Ann Arbor 185
Nanjing 72
Roxbury 66
Lawrence 65
Bari 58
Brussels 57
New York 55
Des Moines 44
Beijing 43
Princeton 40
Inglewood 33
Boardman 26
San Diego 25
Dearborn 24
Hebei 23
Nanchang 21
Dong Ket 20
Shenyang 15
Brooklyn 14
Jiaxing 14
London 14
Changsha 12
Dublin 11
Hefei 11
Redwood City 11
Tianjin 9
Falls Church 7
Helsinki 7
Jinan 7
Kunming 7
San Mateo 7
Ningbo 6
Pune 6
Guangzhou 5
Milan 5
Monmouth Junction 5
San Francisco 5
Taranto 5
Zhengzhou 5
Brno 4
Trani 4
Chongqing 3
Fuzhou 3
Hounslow 3
Leawood 3
Marseille 3
Montignoso 3
Nagareyama 3
Santa Marinella 3
Washington 3
Wuhan 3
Adelfia 2
Altamura 2
Ardabil 2
Augusta 2
Baotou 2
Campobello Di Mazara 2
Chicago 2
Chiswick 2
Fremont 2
Hangzhou 2
Islington 2
Kilburn 2
Los Angeles 2
Mcallen 2
Melbourne 2
Montreal 2
Nulvi 2
Paris 2
Prescot 2
Santiago 2
Sennori 2
Seveso 2
Tokyo 2
Acton 1
Amsterdam 1
Auckland 1
Besana in Brianza 1
Castelnuovo Rangone 1
Castlepollard 1
Chengdu 1
Chions 1
Cincinnati 1
Culver City 1
Esslingen am Neckar 1
Fasano 1
Gioia Del Colle 1
Groningen 1
Haikou 1
Indiana 1
Totale 3.947
Nome #
Effects of Nandrolone in the counteraction of skeletal muscle atrophy in a mouse model of muscle disuse: molecular biology and functional evaluation 137
Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of Duchenne muscular dystrophy: a comparison with the gold standard, α-methyl prednisolone. 128
Contractile efficiency of dystrophic mdx mouse muscle: In vivo and ex vivo assessment of adaptation to exercise of functional end points 119
Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin 118
Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine 113
In vivo longitudinal study of rodent skeletal muscle atrophy using ultrasonography 113
Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options 110
On the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles 109
Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy 109
Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy. 107
Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo 107
Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity 102
Constrained analogues of tocainide as potent skeletal muscle sodium channel blockers towards the development of antimyotonic agents 100
Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia 98
Synthesis of beta-proline like derivatives and their evaluation as sodium channel blockers 97
A long-term treatment with taurine prevents cardiac dysfunction in mdx mice 95
null 90
Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies 90
Searching for novel anti-myotonic agents: Pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide 88
Change of chloride ion channel conductance is an early event of slow-to-fast fibre type transition during unloading-induced muscle disuse 86
null 86
Identification of sites responsible for the potentiating effect of niflumic acid on ClC-Ka kidney chloride channels 83
Paracrine Effects of IGF-1 Overexpression on the Functional Decline Due to Skeletal Muscle Disuse: Molecular and Functional Evaluation in Hindlimb Unloaded MLC/mIgf-1 Transgenic Mice 80
Use-Dependent block of voltage-gated sodium channels by orphenadrine through binding at the local anesthetic receptor 77
null 77
Therapeutic approaches to genetic ion channelopathies and perspectives in drug discovery 75
null 75
null 72
Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle 71
Stereospecific Synthesis of ‘‘para-Hydroxymexiletine’’ and Sodium Channel Blocking Activity Evaluation 71
null 69
null 69
null 68
Dual action of mexiletine and its pyrroline derivatives as skeletal muscle sodium channel blockers and anti-oxidant compounds: Toward novel therapeutic potential 65
Protein Kinase C-Theta Controls the CLC-1 Chloride Channel Function and Skeletal Muscle Phenotype: A Biophysical and Gene Expression Study in Pkc-Theta Null Mice 62
Synthesis and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogs 61
Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo 59
Newly synthesized mexiletine and tocainide analogues are potent use-dependent blockers of skeletal muscle sodium channels: potential implication for antimyotonic activity 58
Ergogenic effect of bcaas and l-alanine supplementation: Proof-of-concept study in a murine model of physiological exercise 57
null 56
A new benzylated proline-like tocainide derivative is a potent use dependent skeletal muscle Na+ channel blocker with a potential antimyotonic activity 56
Potent and stereoselective use-dependent block muscle Na+ channels by a new proline-like tocainide derivative 55
Antitumorali 55
Large screening of newly synthesized Mexiletine and Tocanide analogs as potent use-dependent blockers of skeletal muscle sodium channels: identification of the structural requirements for improving antimyotonic activity 53
Taurine administration to exercised mdx mouse ameliorates fore limb strength and electrophysiological properties of diaphragm and extensor digitorum longus muscles 53
Molecular determinants in mexiletine and tocainide structure to improve therapy of myotonia 51
Potential benefits of taurine in the prevention of skeletal muscle impairment induced by disuse in the hindlimb-unloaded rat 51
Effects of GH secretagogues on resting chloride conductance of aged rat skeletal muscle 50
Chiral mexiletine analogues as skeletal muscle voltage-gated sodium channel blocking agents 50
A new benzylated proline-like tocainide derivative is a potent use-dependent skeletal muscle Na+ channel blocker with a potential anti-myotonic activity 49
Calcium homeostasis is altered in skeletal muscle of spontaneously hypertensive rats cytofluorimetric and gene expression analysis 49
Potent and stereoselective use-dependent block muscle Na+ channels by a new proline-like tocainide derivative 48
null 48
Protein kinase C theta (PKCθ) modulates the ClC-1 chloride channel activity and skeletal muscle phenotype: a biophysical and gene expression study in mouse models lacking the PKCθ 48
Potent and stereoselective use-dependent block of skeletal muscle Na+ channels by a new proline-like tocainide derivative 44
Modification of resting chloride conductance during and after recovery from hindlimb unloading 43
Evaluation of the dual action of new derivatives of mexiletine as usedependent sodium channel blockers and antioxidant: potential therapeutic application in neuromuscular disorders 39
High affinity block of skeletal muscle sodium channels by newly synthesized analogs of tocainide and its proline-like derivatives 39
Incresed rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the miotonic activity in vivo 39
New molecular requirements of Toc derivatives bearing a novel class of Nav1.4 blockers 38
Molecolar determinants in Mexiletine and Tocainide structure to improve therapy of miotonia 35
Modifications of ion channel activity and expression in soleus muscle fibers account for hypogravity-induced functional alterations 35
BCAAs and Di-Alanine supplementation in the prevention of skeletal muscle atrophy: preclinical evaluation in a murine model of hind limb unloading 31
Evaluation of the dual action of new derivatives of mexiletine as use-dependent sodium channel blockers and antioxidant: potential therapeutic application in neuromuscular disorders 30
Isosteric derivates of mexiletine: New potent use-dependent blockers of skeletal muscle sodium channels with potential antimyotonic activity 29
β‐Dystroglycan Restoration and Pathology Progression in the Dystrophic mdx Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation 29
Modifications of ion channel activity and expression in soleus muscle fibers account for hypogravity-induced functional alterations 28
LARGE SCREENING OF NEWLY SYNTHESIZED MEXILETINE AND TOCANIDE ANALOGS AS POTENT USE-DEPENDENT BLOCKERS OF SKELETAL MUSCLE SODIUM CHANNELS: IDENTIFICATION OF THE STRUCTURAL REQUIREMENTS FOR IMPROVING ANTIMYOTONIC ACTIVITY 26
Isosteric derivatives of mexiletine: new potent use-dependent blockers of skeletal muscle sodium channels with potential antimyotonic activity 24
Pharmacological activity of major metabolites of mexiletine on skeletal muscle sodium currents 22
Molecular spatial geometry of CLC-K ligands: optimal requirements towards high affinity channel block 21
Optimal requirements for high affinity and use-dependent block of skeletal muscle sodium channel by n-benzyl analogs of tocainide-like compounds 21
Combined modifications of mexiletine pharmacophores for new lead blockers of Nav1.4 channels 20
Effects of Pleiotrophin Overexpression on Mouse Skeletal Muscles in Normal Loading and in Actual and Simulated Microgravity 18
Inhibition of skeletal muscle sodium currents by Mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile 16
N‑Aryl-2,6-dimethylbenzamides, a new generation of tocainide analogues as blockers of skeletal muscle voltage-gated sodium channels 16
Protein kinase C theta (PKCθ) modulates the ClC-1 chloride channel activity and skeletal muscle phenotype: a biophysical and gene expression study in mouse models lacking the PKCθ. 15
Molecular spatial geometry of CLC-K ligands: optimal requirements towards high affinity channel block 14
Stereospecific synthesis of “para-hydroxymexiletine“ amd sodium channel blocking activity evaluation 12
Blockers of Skeletal Muscle Nav1.4 Channels: From Therapy of Myotonic Syndrome to Molecular Determinants of Pharmacological Action and Back. 9
Branched-Chain Amino Acids and Di-Alanine Supplementation in Aged Mice: A Translational Study on Sarcopenia 8
Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents 7
Growth hormone secretagogues modulate inflammation and fibrosis in mdx mouse model of Duchenne muscular dystrophy 6
Toward precision medicine in myotonic syndromes 2
Totale 4.939
Categoria #
all - tutte 17.209
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.209


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019358 0 0 0 0 0 0 0 0 6 63 135 154
2019/20201.270 205 66 41 108 122 100 166 126 142 65 101 28
2020/2021971 107 37 80 105 74 46 78 46 77 166 99 56
2021/2022536 14 65 5 19 16 42 25 25 41 50 87 147
2022/2023944 119 101 56 83 95 144 7 116 145 14 32 32
2023/2024296 25 52 27 45 39 83 16 9 0 0 0 0
Totale 4.939